Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $40.67

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average rating of “Hold” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $41.4444.

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. HC Wainwright increased their target price on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Truist Financial raised their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Bank of America lifted their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $35.20 on Tuesday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm’s 50-day simple moving average is $28.88 and its two-hundred day simple moving average is $32.17. The stock has a market cap of $2.06 billion, a PE ratio of -4.95 and a beta of 0.79.

Insider Activity

In related news, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider owned 5,141 shares of the company’s stock, valued at $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tsveta Milanova sold 2,872 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $27.02, for a total transaction of $77,601.44. Following the completion of the transaction, the insider owned 34,793 shares of the company’s stock, valued at approximately $940,106.86. The trade was a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AGIO. AQR Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock worth $1,498,000 after purchasing an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after buying an additional 2,920 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals in the 1st quarter worth about $40,000. Goldman Sachs Group Inc. increased its holdings in Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after buying an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in Agios Pharmaceuticals in the 1st quarter worth about $597,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.